am -
pm ET

We Are Here to Support You

Alnylam Assist™ is committed to providing truly personalized support for you. You will have your own dedicated Case Manager to help you have a smooth treatment experience with OXLUMO® (lumasiran) and answer questions you may have along the way. It’s the support you need, when you need it.

Alnylam Assist® - Understanding Your Benefits
Understanding Insurance Benefits

Your Case Manager will thoroughly review your insurance coverage to verify benefits and help you access OXLUMO. We encourage you to call your Case Manager with any questions you may have on an ongoing basis.

Alnylam Assist™ - Financial Assistance Options
Financial Assistance Options

Alnylam Assist™ provides financial assistance options to qualifying individuals. Your Case Manager will work with you to determine eligibility.a

Alnylam AssistTM Patient Assistance Program (PAP)

  Provides OXLUMO at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria.

Alnylam Assist(TM) Commercial Copay Programb

Covers certain out-of-pocket costs for eligible patients with commercial insurance.

Case Managers can also provide information about other organizations that may be able to provide financial assistance.

a  Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

b  Patients with Medicare, Medicaid, or other government sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or otherwise restricted.

Alnylam Assist® - Disease And Treatment Education
Disease and Treatment Education

Disease education can help you and your loved ones make more informed choices about your health. Your Case Manager can connect you with a Patient Education Liaison (PEL), a trained individual who can directly answer questions about primary hyperoxaluria type 1 (PH1) and treatment with OXLUMO, and provide resources and information to help you and your family learn more about this condition. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.

Introduction to Alnylam Assist™

Watch this video to see all that Alnylam Assist™ has to offer.
Alnylam Assist® - Introduction Video
I’m in the patients’ corner, supporting them through challenging times. That’s why I strive to go above and beyond to service those in need.


Renae, Case Manager

Resources for You

Alnylam Assist™ - Downloadable PDF

Download the Alnylam Assist™ Brochure


Alnylam Assist® - Downloadable PDF

Download the OXLUMO Patient Brochure


Who can support me with the Alnylam Assist™ program?

When you and your doctor choose to begin treatment with OXLUMO, you will have a personal Case Manager and access to a Patient Education Liaison (PEL). Meet your Alnylam Assist™ team ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with OXLUMO, we'll work with your healthcare team to start the process.

How to Get Started
Alnylam Assist® Case Manager Kevin

Call Kevin


Monday - Friday,
8am - 6pm ET

Alylam Separator Triangles


The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, pain, itching, and swelling at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.


OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.